These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

855 related articles for article (PubMed ID: 10553730)

  • 1. Antipsychotic-induced weight gain: a comprehensive research synthesis.
    Allison DB; Mentore JL; Heo M; Chandler LP; Cappelleri JC; Infante MC; Weiden PJ
    Am J Psychiatry; 1999 Nov; 156(11):1686-96. PubMed ID: 10553730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ziprasidone augmentation of clozapine in 11 patients.
    Kaye NS
    J Clin Psychiatry; 2003 Feb; 64(2):215-6. PubMed ID: 12633133
    [No Abstract]   [Full Text] [Related]  

  • 3. Review of atypical antipsychotics and weight gain.
    Sussman N
    J Clin Psychiatry; 2001; 62 Suppl 23():5-12. PubMed ID: 11603886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weight gain associated with antipsychotic drugs.
    Ganguli R
    J Clin Psychiatry; 1999; 60 Suppl 21():20-4. PubMed ID: 10548138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Mechanisms of the body weight gain induced by novel antipsychotic drugs and concomitant lipid abnormalities].
    Kostulski A; Wyszogrodzka-Kucharska A; Rabe-Jabłońska J
    Przegl Lek; 2005; 62(9):938-43. PubMed ID: 16541734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weight effects associated with antipsychotics: a comprehensive database analysis.
    Parsons B; Allison DB; Loebel A; Williams K; Giller E; Romano S; Siu C
    Schizophr Res; 2009 May; 110(1-3):103-10. PubMed ID: 19321312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacology of weight gain with antipsychotics.
    Casey DE; Zorn SH
    J Clin Psychiatry; 2001; 62 Suppl 7():4-10. PubMed ID: 11346195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons.
    Fraguas D; Correll CU; Merchán-Naranjo J; Rapado-Castro M; Parellada M; Moreno C; Arango C
    Eur Neuropsychopharmacol; 2011 Aug; 21(8):621-45. PubMed ID: 20702068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atypical antipsychotics and weight gain--a systematic review.
    Taylor DM; McAskill R
    Acta Psychiatr Scand; 2000 Jun; 101(6):416-32. PubMed ID: 10868465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in weight, plasma lipids, and glucose in adults treated with ziprasidone: a comprehensive analysis of pfizer-initiated clinical trials.
    Pappadopulos E; Newcomer JW; Kolluri S
    J Clin Psychiatry; 2012 Jun; 73(6):e742-8. PubMed ID: 22795213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents.
    Maayan L; Correll CU
    J Child Adolesc Psychopharmacol; 2011 Dec; 21(6):517-35. PubMed ID: 22166172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review.
    Simon V; van Winkel R; De Hert M
    J Clin Psychiatry; 2009 Jul; 70(7):1041-50. PubMed ID: 19653979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy and tolerability of clozapine combined with ziprasidone or risperidone.
    Kuwilsky A; Krumm B; Englisch S; Dressing H; Zink M
    Pharmacopsychiatry; 2010 Aug; 43(6):216-20. PubMed ID: 20589598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weight gain--as possible predictor of metabolic syndrome.
    Grahovac T; Ružić K; Dadić-Hero E; Sepić-Grahovac D; Sabljić V
    Psychiatr Danub; 2011 Mar; 23(1):105-7. PubMed ID: 21448110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
    Woods SW; Gueorguieva RV; Baker CB; Makuch RW
    Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.
    Kane JM; Leucht S; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The implications of weight changes with antipsychotic treatment.
    Sussman N
    J Clin Psychopharmacol; 2003 Jun; 23(3 Suppl 1):S21-6. PubMed ID: 12832946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ziprasidone: profile on safety.
    Goodnick PJ
    Expert Opin Pharmacother; 2001 Oct; 2(10):1655-62. PubMed ID: 11825308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Exercising caution in choice of psychotropic drugs. Avoid drug-induced weight gain].
    MMW Fortschr Med; 2002 May; Suppl 2():89. PubMed ID: 12070872
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 43.